乌干达口服疫苗接种的半圈养黑猩猩脊髓灰质炎病毒抗体滴度评估。
Evaluation of poliovirus antibody titers in orally vaccinated semi-captive chimpanzees in Uganda.
作者信息
Mugisha L, Pauli G, Opuda-Asibo J, Joseph O O, Leendertz F H, Diedrich S
机构信息
Chimpanzee Sanctuary & Wildlife Conservation Trust (CSWCT), Entebbe, Uganda.
出版信息
J Med Primatol. 2010 Apr;39(2):123-8. doi: 10.1111/j.1600-0684.2010.00400.x. Epub 2010 Jan 25.
BACKGROUND
To understand immunological responses in chimpanzees vaccinated with live-attenuated vaccine (oral polio vaccine; OPV), serum neutralizing antibodies against poliovirus types 1, 2, and 3 were investigated over time.
METHODS
The neutralizing antibody titers against poliovirus types 1, 2, and 3 were determined by microneutralization test using 100 ID(50) of poliovirus types 1, 2, and 3 (Sabin strains).
RESULTS
Neutralizing antibodies against poliovirus types 1, 2, and 3 were detected in 85.7%, 71.4%, and 65% of the serum from 42 chimpanzees tested 9 years post-vaccination. The neutralizing antibody titers in chimpanzees were similar to the documented levels in human studies as an indicator of vaccine efficacy.
CONCLUSIONS
This study reveals persistence of neutralizing antibodies in chimpanzees for at least 9 years after vaccination with OPV. This first study in chimpanzees provides useful information for the evaluation of the success of vaccination with OPV in other captive apes.
背景
为了解接种减毒活疫苗（口服脊髓灰质炎疫苗；OPV）的黑猩猩的免疫反应，对1型、2型和3型脊髓灰质炎病毒的血清中和抗体进行了长期研究。
方法
使用100个半数感染剂量（ID50）的1型、2型和3型脊髓灰质炎病毒（萨宾株），通过微量中和试验测定针对1型、2型和3型脊髓灰质炎病毒的中和抗体滴度。
结果
在接种疫苗9年后检测的42只黑猩猩的血清中，分别有85.7%、71.4%和65%检测到针对1型、2型和3型脊髓灰质炎病毒的中和抗体。黑猩猩体内的中和抗体滴度与人体研究中记录的作为疫苗效力指标的水平相似。
结论
本研究揭示了黑猩猩接种OPV后至少9年中和抗体持续存在。这项在黑猩猩身上进行的首次研究为评估其他圈养猿类接种OPV的成功情况提供了有用信息。
Zotero 插件